Tumor Necrosis Factor Alpha Inhibitors Market Research Report–Forecast till 2023

Tumor Necrosis Factor Alpha Inhibitors Market Research Report: By Drug (Humira, Remicade), By Disease Type (Alzheimer's Diseases, Multiple Sclerosis), By Route Of Administration, By Stage Of Clinical Trials, By Application – Global Forecast Till 2023

ID: MRFR/Pharma/4090-HCR | February 2021 | Region: Global | 90 pages

Market Scenario:


The tumor necrosis factor alpha (TNF-a) inhibitors represent one of the major treatment methods for inflammatory diseases. Globally, this drug class is known to be the most successful drugs in the overall pharmaceutical industry. Several conditions such as inflammations, rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and seronegative spondyloarthropathies, can be treated with the help of these drugs. The total sales of the top three blockbuster TNF-alpha inhibitors namely Remicade, Enbrel, and Humira had surpassed USD 32 billion in 2016.


Xalud’s lead product XT-150 harnesses the power of the body’s potent anti-inflammatory protein IL-10 to treat inflammatory diseases of the central nervous system (CNS) and joints. XT-150 is in the stage of the preclinical trials for multiple sclerosis, neuropathic pain, and osteoarthritis. In leading rodent model study for neuropathic pain XT-150 has been highly efficacious. Single injection delivers it into the fluid surrounding the spinal cord ensuring that the therapy reaches its target.


In the present scenario, developing countries have stringent regulatory requirements for approval of a new drug. It is a difficult task for marketing authorization application to get single regulatory for a new drug product which belongs to various categories of drugs such as NCE, biologicals, controlled drugs, etc. Therefore, the knowledge of precise and detailed regulatory requirements for market authorization application of different categories of drugs should be known to establish a suitable regulatory strategy. There is a need for pronounce and a fine balance between the persistence of gaining market access to pharmaceuticals, to protect the public health and facilitate healthy growth of pharmaceutical manufacturers.


The global tumor necrosis factor alpha inhibitors market is expected to grow at a CAGR of approximately 7.1% during the forecast period 2017-2023.


Intended Audience



  • Tumor Necrosis Factor Alpha Inhibitors Drug Suppliers

  • Tumor Necrosis Factor Alpha Inhibitors Drug Manufacturers

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities

  • Research Methodology


Sources: Annual reports, Press release, White paper, and Company presentation


tumor necrosis Market
Segmentation                                                                                                


The global tumor necrosis factor alpha inhibitors market is segmented on the basis of the drug, disorder type, route of administration, stage of clinical trials, and application.


On the basis of the drug, the global tumor necrosis factor alpha inhibitors market is segmented into Humira, Enbrel, Remicade, and others


On the basis of the disease type, the global tumor necrosis factor alpha inhibitors market is segmented into Alzheimer's diseases, Parkinson's diseases, ischemic stroke, multiple sclerosis, and others.


By the route of administration, the global tumor necrosis factor alpha inhibitors market is segmented into oral, subcutaneous, intravenous, and others.


On the basis of the stage of clinical trials, the global tumor necrosis factor alpha inhibitors market is segmented into the preclinical trial, phase 1 clinical trial, phase 2 clinical trial, phase 3 clinical trial, and phase 4 clinical trial.


On the basis of the application, the global tumor necrosis factor alpha inhibitors market is segmented into medicine, scientific research, and others.


Regional Analysis


The global tumor necrosis factor alpha inhibitors market is segmented as the Americas, Europe, Asia Pacific and the Middle East and Africa.


The Americas is projected to hold the largest share of the global tumor necrosis factor alpha inhibitors market. P2D Biosciences, a US-based company, received $ 2.3 million funding from NIH (National Institutes of Health) with four grants. The grants include the development of new drugs for the treatment of acute leukemia and Alzheimer's disease and a new drug to improve stem cell transplant therapy for treating leukemia and lymphomas, which will help P2D to develop medical advances that improve the lives and health of people who are affected with these diseases.


Europe is expected to capture the second lead in this market in the coming five years owing to substantial technological advancements. In 2016, LEO Pharma, a Denmark based company entered biologics through a strategic partnership with AstraZeneca. The partnership will help LEO Pharma enhance their product portfolio. A strategic alliance with a healthcare giant will help LEO pharma expand their geographic presence and become a world leader in dermatology segment.


Moreover, Asia Pacific is expected to witness the fastest growth rate over the forecast period. The Middle East and Africa are also expected to show healthy growth in the coming five years.


Key Players


In May 2016, Pfizer acquires Anacor for its inflammatory & immunology portfolio. Anacor is a biopharmaceutical company focused on small molecule therapeutics from its boron chemistry platform, and its asset Crisaborole is in FDA review if approved will be a first-line treatment option for patients with atopic dermatitis. They have entered into a definitive merger agreement under which Pfizer will acquire Anacor for approximately $5.2 billion which assumes the conversion of Anacor’s outstanding convertible notes. Anacor will be a strong fit with Pfizer’s innovative business due to the strategic focus on inflammation and immunology and is expected to enhance near-term revenue growth for the innovative business.


Some of key the players in the global tumor necrosis factor alpha inhibitors market are AbbVie Inc. (U.S.),  Ablynx (Belgium), Apogenix GmBH (Germany), AryoGen Biopharma (U.S.), Bionovis (Brazil), CASI Pharmaceuticals (U.S.), Celltrion Healthcare (South Korea.), Celgene Corporation (U.S.), Delenex Therapeutics (Switzerland), Dexa Medica (Indonesia), EPIRUS Biopharmaceuticals (U.S.), Janssen Biotech (U.S.), GlaxoSmithKline Inc. (U.S.), HanAll Biopharma (South Korea.), Intas Pharmaceuticals (India), LEO Pharma (Denmark), LG Life Sciences (U.S.), MedImmune (U.S.), Momenta Pharmaceuticals (U.S.), Novartis AG (Switzerland), Sanofi-Aventis (France), Zydus Cadila (India), and others.



Frequently Asked Questions (FAQ) :


Tumor Necrosis Factor Alpha Inhibitors Are A Major Treatment Method For Inflammatory Diseases, Including Rheumatoid Arthritis And Inflammatory Bowel Disease.

The Tumor Necrosis Factor Alpha Inhibitors Market is expected to exhibit a strong 7.1% CAGR over the forecast period from 2017 to 2023.

The growing prevalence of autoimmune conditions is likely to be a major driver for the market.

The Americas Hold the Largest Share In The Global Market.

Leading Players In The Tumor Necrosis Factor Alpha Inhibitors Market Include Casi Pharmaceuticals, Abbvie, And Ablynx, Among Others.

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Stage of clinical trials Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Tumor Necrosis Factor Alpha Inhibitors Market, by Drug

6.1 Introduction

6.2 Humira

6.2.1 Market Estimates & Forecast, 2016 – 2023

6.3 Enbrel

6.3.1 Market Estimates & Forecast, 2016 – 2023

6.4 Remicade

6.4.1 Market Estimates & Forecast, 2016 – 2023

6.5 Others

Chapter 7. Global Tumor Necrosis Factor Alpha Inhibitors Market, by Disease type

7.1 Introduction

7.2 Alzheimer's diseases

7.2.1 Market Estimates & Forecast, 2017 – 2023

7.3 Parkinson's diseases

7.3.1 Market Estimates & Forecast, 2017 – 2023

7.4 Ischemic stroke

7.4.1 Market Estimates & Forecast, 2017 – 2023

7.5 Multiple sclerosis

7.5.1 Market Estimates & Forecast, 2017 – 2023

7.6 Others

Chapter 8. Global Tumor Necrosis Factor Alpha Inhibitors Market, by Route of administration

8.1 Introduction

8.2 Oral

8.2.1 Market Estimates & Forecast, 2017 – 2023

8.3 Subcutaneous

8.3.1 Market Estimates & Forecast, 2017 – 2023

8.4 Intravenous

8.4.1 Market Estimates & Forecast, 2017 – 2023

8.5 Others

Chapter 9. Global Tumor Necrosis Factor Alpha Inhibitors Market, by Stage of clinical trials

9.1 Introduction

9.2 Preclinical trial

9.2.1 Market Estimates & Forecast, 2017 – 2023

9.3 Phase 1 clinical trial

9.3.1 Market Estimates & Forecast, 2017 – 2023

9.4 Phase 2 clinical trial

9.4.1 Market Estimates & Forecast, 2017 – 2023

9.5 Phase 3 clinical trial

9.5.1 Market Estimates & Forecast, 2017 – 2023

9.6 Phase 4 clinical trial

9.6.1 Market Estimates & Forecast, 2017 – 2023

Chapter 10. Global Tumor Necrosis Factor Alpha Inhibitors Market, by Application

10.1 Introduction

10.2 Medicine

10.2.1 Market Estimates & Forecast, 2017 – 2023

10.3 Scientific research

10.3.1 Market Estimates & Forecast, 2017 – 2023

10.4 Others

Chapter. 11 Global Tumor Necrosis Factor Alpha Inhibitors Market, by Region

11.1 Introduction

11.2 Americas

11.2.1 North America

11.2.1.1 U.S.

11.2.1.2 Canada

11.2.2 South America

11.3 Europe

11.3.1 Western Europe

11.3.1.1 Germany

11.3.1.2 France

11.3.1.3 Italy

11.3.1.4 Spain

11.3.1.5 U.K

11.3.1.6 Rest of Western Europe

11.3.2 Eastern Europe

11.4 Asia Pacific

11.4.1 Japan

11.4.2 China

11.4.3 India

11.4.4 Australia

11.4.5 Republic of Korea

11.4.6 Rest of Asia Pacific

11.5 The Middle East & Africa

11.5.1 United Arab Emirates

11.5.2 Saudi Arabia

11.5.3 Rest of the Middle East & Africa

Chapter 12 Company Landscape

12.1 Introduction

12.2 Market Share Analysis

12.3 Key Development & Strategies

12.3.1 Key Developments

Chapter 13 Company Profiles

13.1 AbbVie Inc.

13.1.1 Company Overview

13.1.2 Route of administration Overview

13.1.3 Financials

13.1.4 SWOT Analysis

13.2 Ablynx

13.2.1 Company Overview

13.2.2 Route of administration Overview

13.2.3 Financial Overview

13.2.4 Key Developments

13.2.5 SWOT Analysis

13.3 Apogenix GmBH

13.3.1 Company Overview

13.3.2 Route of administration Overview

13.3.3 Financial Overview

13.3.4 Key Development

13.3.5 SWOT Analysis

13.4 Celgene Corporation

13.4.1 Company Overview

13.4.2 Route of administration/Business Segment Overview

13.4.3 Financial Overview

13.4.4 Key Development

13.4.5 SWOT Analysis

13.5 GlaxoSmithKline Inc.

13.5.1 Company Overview

13.5.2 Route of administration Overview

13.5.3 Financial overview

13.5.4 Key Developments

13.6 Novartis AG

13.6.1 Company Overview

13.6.2 Route of administration Overview

13.6.3 Financial Overview

13.6.4 Key Developments

13.7 Sanofi-Aventis

13.7.1 Overview

13.7.2 Route of administration Overview

13.7.3 Financials

13.7.4 Key Developments

13.7.5 SWOT Analysis

13.8 Zydus Cadila

13.8.1 Company Overview

13.8.2 Route of administration/Business Segment Overview

13.8.3 Financial Overview

13.8.4 Key Development

13.8.5 SWOT Analysis

13.9 Delenex Therapeutics

13.9.1 Company Overview

13.9.2 Route of administration Overview

13.9.3 Financial overview

13.9.4 Key Developments

13.10 Others

Chapter 14 MRFR Conclusion

14.1 Key Findings

14.1.1 From CEO’s View Point

14.1.2 Unmet Needs of the Market

14.2 Key Companies to Watch

14.3 Prediction of Pharmaceutical industry

Chapter 15 Appendix
LIST OF TABLES

Table 1 Tumor Necrosis Factor Alpha Inhibitors Industry Synopsis, 2017 – 2023

Table 2 Tumor Necrosis Factor Alpha Inhibitors Market Estimates and Forecast, 2017 – 2023, (USD Million)

Table 3 Tumor Necrosis Factor Alpha Inhibitors Market by Region, 2017 – 2023, (USD Million)

Table 4 Tumor Necrosis Factor Alpha Inhibitors Market by Drug, 2017 – 2023, (USD Million)

Table 5 Tumor Necrosis Factor Alpha Inhibitors Market by Disease type, 2017 – 2023, (USD Million)

Table 6 Tumor Necrosis Factor Alpha Inhibitors Market by Route of administration, 2017 – 2023, (USD Million)

Table 7 Tumor Necrosis Factor Alpha Inhibitors Market by Stage of clinical trials, 2017 – 2023, (USD Million)

Table 8 Tumor Necrosis Factor Alpha Inhibitors Market by Applications, 2017 – 2023, (USD Million)

Table 9 North America Tumor Necrosis Factor Alpha Inhibitors Market by Drug, 2017 – 2023, (USD Million)

Table 10 North America Tumor Necrosis Factor Alpha Inhibitors Market by Disease type, 2017 – 2023, (USD Million)

Table 11 North America Tumor Necrosis Factor Alpha Inhibitors Market by Route of administration, 2017 – 2023, (USD Million)

Table 12 North America Tumor Necrosis Factor Alpha Inhibitors Market by Stage of clinical trials, 2017 – 2023, (USD Million)

Table 13 North America Tumor Necrosis Factor Alpha Inhibitors Market by Application, 2017 – 2023, (USD Million)

Table 14 US Tumor Necrosis Factor Alpha Inhibitors Market by Drug, 2017 – 2023, (USD Million)

Table 15 US Tumor Necrosis Factor Alpha Inhibitors Market by Disease type, 2017 – 2023, (USD Million)

Table 16 US Tumor Necrosis Factor Alpha Inhibitors Market by Route of administration, 2017 – 2023, (USD Million)

Table 17 US Tumor Necrosis Factor Alpha Inhibitors Market by Stage of clinical trials, 2017 – 2023, (USD Million)

Table 18 US Tumor Necrosis Factor Alpha Inhibitors Market by Application, 2017 – 2023, (USD Million)

Table 19 Canada Tumor Necrosis Factor Alpha Inhibitors Market by Drug, 2017 – 2023, (USD Million)

Table 20 Canada Tumor Necrosis Factor Alpha Inhibitors Market by Disease type, 2017 – 2023, (USD Million)

Table 21 Canada Tumor Necrosis Factor Alpha Inhibitors Market by Route of administration, 2017 – 2023, (USD Million)

Table 22 Canada Tumor Necrosis Factor Alpha Inhibitors Market by Stage of clinical trials, 2017 – 2023, (USD Million)

Table 23 Canada Tumor Necrosis Factor Alpha Inhibitors Market by Application, 2017 – 2023, (USD Million)

Table 24 South America Tumor Necrosis Factor Alpha Inhibitors Market by Drug, 2017 – 2023, (USD Million)

Table 25 South America Tumor Necrosis Factor Alpha Inhibitors Market by Disease type, 2017 – 2023, (USD Million)

Table 26 South America Tumor Necrosis Factor Alpha Inhibitors Market by Route of administration, 2017 – 2023, (USD Million)

Table 27 South America Tumor Necrosis Factor Alpha Inhibitors Market by Stage of clinical trials, 2017 – 2023, (USD Million)

Table 28 South America Tumor Necrosis Factor Alpha Inhibitors Market by Application, 2017 – 2023, (USD Million)

Table 29 Europe Tumor Necrosis Factor Alpha Inhibitors Market by Drug, 2017 – 2023, (USD Million)

Table 30 Europe Tumor Necrosis Factor Alpha Inhibitors Market by Disease type, 2017 – 2023, (USD Million)

Table 31 Europe Tumor Necrosis Factor Alpha Inhibitors Market by Route of administration, 2017 – 2023, (USD Million)

Table 32 Europe Tumor Necrosis Factor Alpha Inhibitors Market by Stage of clinical trials, 2017 – 2023, (USD Million)

Table 33 Europe Tumor Necrosis Factor Alpha Inhibitors Market by Application, 2017 – 2023, (USD Million)

Table 34 Western Europe Tumor Necrosis Factor Alpha Inhibitors Market by Drug, 2017 – 2023, (USD Million)

Table 35 Western Europe Tumor Necrosis Factor Alpha Inhibitors Market by Disease type, 2017 – 2023, (USD Million)

Table 36 Western Europe Tumor Necrosis Factor Alpha Inhibitors Market by Route of administration, 2017 – 2023, (USD Million)

Table 37 Western Europe Tumor Necrosis Factor Alpha Inhibitors Market by Stage of clinical trials, 2017 – 2023, (USD Million)

Table 38 Western Europe Tumor Necrosis Factor Alpha Inhibitors Market by Application, 2017 – 2023, (USD Million)

Table 39 Eastern Europe Tumor Necrosis Factor Alpha Inhibitors Market by Drug, 2017 – 2023, (USD Million)

Table 40 Eastern Europe Tumor Necrosis Factor Alpha Inhibitors Market by Disease type, 2017 – 2023, (USD Million)

Table 41 Eastern Europe Tumor Necrosis Factor Alpha Inhibitors Market by Route of administration, 2017 – 2023, (USD Million)

Table 42 Eastern Europe Tumor Necrosis Factor Alpha Inhibitors Market by Stage of clinical trials, 2017 – 2023, (USD Million)

Table 43 Eastern Europe Tumor Necrosis Factor Alpha Inhibitors Market by Application, 2017 – 2023, (USD Million)

Table 44 Asia Pacific Tumor Necrosis Factor Alpha Inhibitors Market by Drug, 2017 – 2023, (USD Million)

Table 45 Asia Pacific Tumor Necrosis Factor Alpha Inhibitors Market by Disease type, 2017 – 2023, (USD Million)

Table 46 Asia Pacific Tumor Necrosis Factor Alpha Inhibitors Market by Route of administration, 2017 – 2023, (USD Million)

Table 47 Asia Pacific Tumor Necrosis Factor Alpha Inhibitors Market by Stage of clinical trials, 2017 – 2023, (USD Million)

Table 48 Asia Pacific Tumor Necrosis Factor Alpha Inhibitors Market by Application, 2017 – 2023, (USD Million)

Table 49 The Middle East & Africa Tumor Necrosis Factor Alpha Inhibitors Market by Drug, 2017 – 2023, (USD Million)

Table 50 The Middle East & Africa Tumor Necrosis Factor Alpha Inhibitors Market by Disease type, 2017 – 2023, (USD Million)

Table 51 The Middle East & Africa Tumor Necrosis Factor Alpha Inhibitors Market by Route of administration, 2017 – 2023, (USD Million)

Table 52 The Middle East & Africa Tumor Necrosis Factor Alpha Inhibitors Market by Stage of clinical trials, 2017 – 2023, (USD Million)

Table 53 The Middle East & Africa Tumor Necrosis Factor Alpha Inhibitors Market by Application, 2017 – 2023, (USD Million)

LIST OF FIGURES
Figure 1 Research Process

Figure 2 Segmentation for Tumor Necrosis Factor Alpha Inhibitors Market

Figure 3 Segmentation Market Dynamics for Tumor Necrosis Factor Alpha Inhibitors Market

Figure 4 Global Tumor Necrosis Factor Alpha Inhibitors Market Share, by Drug 2016

Figure 5 Global Tumor Necrosis Factor Alpha Inhibitors Market Share, by Disease type 2016

Figure 6 Global Tumor Necrosis Factor Alpha Inhibitors Market Share, by Route of administration, 2016

Figure 8 Global Tumor Necrosis Factor Alpha Inhibitors Market Share, by Stage of clinical trials, 2016

Figure 9 Global Tumor Necrosis Factor Alpha Inhibitors Market Share, by Applications, 2016

Figure 10 Global Tumor Necrosis Factor Alpha Inhibitors Market Share, by Region, 2016

Figure 11 North America Tumor Necrosis Factor Alpha Inhibitors Market Share, by Country, 2016

Figure 12 Europe Tumor Necrosis Factor Alpha Inhibitors Market Share, by Country, 2016

Figure 13 Asia Pacific Tumor Necrosis Factor Alpha Inhibitors Market Share, by Country, 2016

Figure 14 The Middle East & Africa Tumor Necrosis Factor Alpha Inhibitors Market Share, by Country, 2016

Figure 15 Global Tumor Necrosis Factor Alpha Inhibitors Market: Company Share Analysis, 2016 (%)

Figure 16 AbbVie Inc. : Key Financials

Figure 17 AbbVie Inc. : Segmental Revenue

Figure 18 AbbVie Inc.: Geographical Revenue

Figure 19 Ablynx: Key Financials

Figure 20 Ablynx: Segmental Revenue

Figure 21 Ablynx: Geographical Revenue

Figure 22 Apogenix GmBH: Key Financials

Figure 23 Apogenix GmBH: Segmental Revenue

Figure 24 Apogenix GmBH: Geographical Revenue

Figure 25 Celgene Corporation: Key Financials

Figure 26 Celgene Corporation: Segmental Revenue

Figure 27 Celgene Corporation: Geographical Revenue

Figure 28 GlaxoSmithKline Inc.: Key Financials

Figure 29 GlaxoSmithKline Inc.: Segmental Revenue

Figure 30 GlaxoSmithKline Inc.: Geographical Revenue

Figure 32 Novartis AG: Key Financials

Figure 33 Novartis AG: Segmental Revenue

Figure 34 Novartis AG: Geographical Revenue

Figure 35 Sanofi-Aventis: Key Financials

Figure 36 Sanofi-Aventis: Segmental Revenue

Figure 37 Sanofi-Aventis: Geographical Revenue

Figure 38 Zydus Cadila: Key Financials

Figure 39 Zydus Cadila: Segmental Revenue

Figure 40 Zydus Cadila: Geographical Revenue

Figure 41 Delenex Therapeutics: Key Financials

Figure 42 Delenex Therapeutics: Segmental Revenue

Figure 43 Delenex Therapeutics: Geographical Revenue